|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. For example, here is how to disable FireFox ad content blocking while on Silicon Investor.|
IPCI is at current price one of the most attractive and cheapest Biotech out there and IPCI is massive oversold with an RSI of 27 .
IPCI has 7 ANDA´s awaiting FDA approval 4 of them exceed the 36 Month average approval time by many months means FDA approvals could come any day now . They have another two Mega Drugs called Rexista & Regabatin which are ready to enter Phase 3 later this year .
Float is around 10 M and they have a low Market Cap of just $66 M makes IPCI one of the most attractive Play in the US Biotech Sector .
This Low Float Gem has the Potential to run into Double Digits with FDA approvals which means Deep Profitability for IPCI .GL
Cash: $7.2 M
Burn-Rate: $1.5 M per Quarter
Shares Out: 23.3 M
New Fact Sheet:
We currently have seven Abbreviated New Drug Applications awaiting FDA approval.
These include generics of Effexor XR®, Protonix ®' Glucophage ® XR,Seroquel XR®, Lamictaf® XR Keppra XR® and Pristiq® .Together, these products represent approximately $4.1 billion of branded and generic sales.
The company received approval of its first generic product, Focalin XR, in November 2013 and its marketing partner Par Pharmaceutics immediately launched the drug at the end of November 2013. The company has a total of seven controlled-release generic drugs that are awaiting FDA approval.
Read more at stockhouse.com
|© 2019 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|